Rehmannioside A

Rehmannioside A is a compound that can be isolated from Rehmanniae radix. Rehmannioside A is an inhibitor of CYP3A4, 2C9 and 2D6, with IC50 values of 10.08, 12.62 and 16.43 μM, respectively. Rehmannioside A has anti-inflammatory, antioxidant, anti-apoptosis, anti-ferroptosis, cognitive improvement and neuroprotective activities. Rehmannioside A can be used for the research of nervous system and inflammation-related diseases[1][2][3][4].

Product Specifications

CAS Number

[81720-05-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Bcl-2 Family; COX; Cytochrome P450; Ferroptosis; Lactate Dehydrogenase; MEK; NF-κB; NO Synthase; p38 MAPK; PARP; PERK; Reactive Oxygen Species (ROS) ; SOD

Type

Natural Products

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Rehmannioside-A.html

Purity

99.96

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

Smiles

OC[C@@]1([C@]([C@@H]2O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]([C@H]3O)CO[C@H]([C@@H]([C@H]4O)O)O[C@@H]([C@@H]4O)CO)([H])[C@](C=CO2)([H])[C@@H]5O)[C@@]5([H])O1

Molecular Formula

C21H32O15

Molecular Weight

524.47

Precautions

H302, H315, H319, H335

References & Citations

[1]Xiao S, et al. Rea regulates microglial polarization and attenuates neuronal apoptosis via inhibition of the NF-κB and MAPK signalings for spinal cord injury repair. J Cell Mol Med. 2021 Feb;25 (3) :1371-1382.|[2]Huai L, et al. Rehmannioside A protects against high glucose-induced apoptosis and oxidative stress of renal tubular epithelial cells by inhibiting the MAPK pathway. Tropical Journal of Pharmaceutical Research, 2021, 20 (8) : 1553-1558.|[3]Wang C, et al. Rehmannioside A inhibits the activity of CYP3A4, 2C9 and 2D6 in vitro. Xenobiotica. 2024 Apr;54 (4) :195-200.|[4]Fu C, et al. Rehmannioside A improves cognitive impairment and alleviates ferroptosis via activating PI3K/AKT/Nrf2 and SLC7A11/GPX4 signaling pathway after ischemia. J Ethnopharmacol. 2022 May 10;289:115021.